Drug Discovery Today

Article	Citations
Transitioning biomedical research toward human-centric methodologies: systems-based strategies	179
A new approach to treat type 2 diabetes – Targeting a non-insulin dependent pathway	174
Contents page	162
Artificial intelligence (AI) and alternative variables (AV) in drug discovery: A promising alliance	145
Applications of density functional theory in COVID-19 drug modeling	144
Obesity and insulin resistance: Pathophysiology and treatment	121
Therapies for Inherited Retinal Dystrophies: What is Enough?	119
Contents page	116
Contents page	104
The ethics of animal research and testing: A US perspective	98
Neoteric solvents for the pharmaceutical industry: an update	98
A personalized pharmaco-epistatic network model of precision medicine	95
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	92
Corrigendum to “A review of in vitro and in vivo methods and their correlations to assess mouthfeel of solid oral dosage forms” [Drug Discov. Today 26(3) (2021) 740–753]	91
A review of in vitro and in vivo methods and their correlations to assess mouthfeel of solid oral dosage forms	89
Contents page 2	88
Contents page 2	86
The Value in Failure	86
Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get?	83
Benefits of hybrid QM/MM over traditional classical mechanics in pharmaceutical systems	76
Crystallographic landscape provides molecular insights into the modes of action of diverse ROR-γt modulators	76
Drug discovery for epigenetics targets	75
Generic dry powder inhalers bioequivalence: Batch–to-batch variability insights	74
Contents page 1	70
Trends, challenges, and success factors in pharmaceutical portfolio management: Cognitive biases in decision-making and their mitigating measures	70

Industry perspective on the nonclinical safety assessment of heterobifunctional degraders	68
Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)	67
The promise of crowdfunding to finance R&D of novel diagnostics and therapeutics for incurable diseases	66
Advancements in small molecule drug design: A structural perspective	64
Emergent treatments for β-thalassemia and orphan drug legislations	63
Antibody–drug conjugates: What drives their progress?	63
Oral peptide delivery: challenges and the way ahead	63
COVID-19 and fibrosis: Mechanisms, clinical relevance, and future perspectives	63
Neurotrophin-targeted therapeutics: A gateway to cognition and more?	63
Contents page	61
Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned	61
Improving the ability of antimicrobial susceptibility tests to predict clinical outcome accurately: Adding metabolic evasion to the equation	61
An exploration of alternative therapeutic targets for aortic disease in Marfan syndrome	61
Four scenarios for the future of medicines and social policy in 2030	60
Strengthening Molecular Glues: Design Strategies for Improving Thalidomide Analogs as Cereblon Effectors and Anticancer Agents	60
How can we unleash the potential of external controls in clinical trials?	59
3D printing of biologics—what has been accomplished to date?	55
Contents page	55
Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes	54
Innovation in breakthrough drugs and vaccines: Development risk, patient impact, and value	54
A pleiotropic–epistatic entangelement model of drug response	53
Novel and investigational therapies for wet and dry age-related macular degeneration	53
The potential value of 5-androstenediol in countering acute radiation syndrome	53
Fighting AMR with Host Immune Response Technology	53
Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity	52
Fiduciary responsibility	52
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	52
Stimuli-sensitive drug delivery systems for site-specific antibiotic release	51
Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?	51
Multiorgan locked-state model of chronic diseases and systems pharmacology opportunities	50
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	47
Recent trends in interorganizational deal networks in pharmaceutical and biotechnology industries	47
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	47
Role of innovation in pharmaceutical regulation: A proposal for principles to evaluate EU General Pharmaceutical Legislation from the innovator perspective	46
Antitoxin nanoparticles: design considerations, functional mechanisms, and applications in toxin neutralization	46
Forty years of combinatorial technology	45
The transmembrane domains of GPCR dimers as targets for drug development	45
Ebola outbreaks: A stress test of the preparedness of medicines regulatory systems for public health crises	45
Data standards in drug discovery: A long way to go	43
The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	42
Pharma innovation: how evolutionary economics is shaping the future of pharma R&D	42
Revisiting the GBB reaction and redefining its relevance in medicinal chemistry: A review	42
Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy	41
Drug repurposing: Known knowns to unknown unknowns – Network analysis of the repurposome	41
Academic drug discovery in an age of research abundance, and the curious case of chemical screens toward drug repositioning	41
Synthesis and modification of bio-derived antibacterial Ag and ZnO nanoparticles by plants, fungi, and bacteria	40
How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons	40
Machine Learning guided early drug discovery of small molecules	39
Increased contribution of small companies to late-entry drugs: a changing trend in FDA-approved drugs during the 2020s	39
New Generation Anti-Obesity Pharmacotherapy: Companion or Competitor to Metabolic bariatric Surgery?	39

New trends for osteoarthritis: Biomaterials, models and modeling	38
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	38
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	38
AlphaFold, allosteric, and orthosteric drug discovery: Ways forward	38
MAT2A inhibition combats metabolic and transcriptional reprogramming in cancer	37
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	37
Application of proteomics for novel drug discovery and risk prediction optimisation in stroke and myocardial infarction: a review of in-human studies	37
Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitis	36
Key considerations in formulation development for gene therapy products	36
Bioresponsive drug delivery systems	36
Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2	36
General aspects of powder rheology applied to pharmaceutical formulations	36
Inflammation, stress and depression: An exploration of ketamine’s therapeutic profile	35
Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases	35
Toward the institutionalization of quantum computing in pharmaceutical research	34
Impact of fenofibrate on NAFLD/NASH: A genetic perspective	34
Nicotinamide N-methyl transferase (NNMT): An emerging therapeutic target	34
R&D efficiency of leading pharmaceutical companies – A 20-year analysis	34
Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants	34
Trends in small molecule drug properties: A developability molecule assessment perspective	34
PHLPPs: Emerging players in metabolic disorders	34
Best practices for artificial intelligence in life sciences research	34
Mitochondrial dysfunction: A potential target for Alzheimer’s disease intervention and treatment	34
Which factors matter the most? Revisiting and dissecting antibody therapeutic doses	33
Sunitinib and its effect in the cardiovascular system	33
Can preclinical drug development help to predict adverse events in clinical trials?	33
Web resources facilitate drug discovery in treatment of COVID-19	33
Identification of biological targets through the correlation between cell line chemosensitivity and protein expression pattern	33
Specificity of pharmacokinetic modeling of nanomedicines	33
Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors	33
Integrating heterogeneous data to facilitate COVID-19 drug repurposing	33
Modulation of serine/threonine-protein phosphatase 1 (PP1) complexes: A promising approach in cancer treatment	33
Drugging the ‘undruggable’. Therapeutic targeting of protein–DNA interactions with the use of computer-aided drug discovery methods	32
Stromal disruption facilitating invasion of a ‘nano-arsenal’ into the solid tumor	32
Artificial intelligence and the future of life sciences	32
Repurposing antidepressants for anticancer drug discovery	32
Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy	31
Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling	31
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	31
Targeting Ca2+ signaling: A new arsenal against cancer	31
Structural basis of HIV inhibition by L-nucleosides: Opportunities for drug development and repurposing	31
Emerging role of oncolytic viruses and stem cells in gene therapy: Should they be integrated?	31
Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective	31
Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory	31
Experimental murine models of brainstem gliomas	31
Repurposing drugs as COVID-19 therapies: A toxicity evaluation	30
Selenium as an emerging versatile player in heterocycles and natural products modification	30
Recent advances in dual-ligand targeted nanocarriers for cancer therapy	30
How doppelgänger effects in biomedical data confound machine learning	30
Drug repurposing for stroke intervention	30
Current and future approaches for in vitro hit discovery in diabetes mellitus	29
PROTACting the kinome with covalent warheads	29
Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders	29
CRISPR/Cas9 in the era of nanomedicine and synthetic biology	29
Prospects of halofuginone as an antiprotozoal drug scaffold	29
Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy	29
Concepts and applications of chemical fingerprint for hit and lead screening	29
The current status of COVID-19 vaccines. A scoping review	29
Patents, trade secrets and pricing	29
Deep learning methods for molecular representation and property prediction	29
Role of transcription termination factor Rho in anti-tuberculosis drug discovery	28
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	28
Immunoconjugates and bispecific antibodies: Trends in therapeutic success and commercial focus	28
Learning from COVID-19: How drug hunters can prepare for the next pandemic	27
Recent trends in STING modulators: Structures, mechanisms, and therapeutic potential	27
Targeting the endocannabinoid system: Structural determinants and molecular mechanism of allosteric modulation	27
ATP-binding cassette efflux transporters and MDR in cancer	27
Targeting histone deacetylases: Emerging applications beyond cancer	27
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	27
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	27
Peptide modulators of cell migration: Overview, applications and future development	27
The recent progress of deep-learning-based in silico prediction of drug combination	27
Models and approaches to comprehend and address glial inflammation following spinal cord injury	27
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	27
CIPDB: A biological structure databank for studying cation and π interactions	27
Native mass spectrometry-directed drug discovery: Recent advances in investigating protein function and modulation	27
Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment	26
Antibody–drug conjugates: prospects for the next generation	26
The identification of essential cellular genes is critical for validating drug targets	26
Beyond CL and VSS: A comprehensive approach to human pharmacokinetic predictions	26

Mainstream psychiatry reinstates therapeutic ventures of the remote past	26
Redefining what it means to age – the impact to society and pharmaceutical industry	26
Best practices for machine learning in antibody discovery and development	26
Three-dimensional cell culture: Future scope in cancer vaccine development	26
Peptides as innovative strategies to combat drug resistance in cancer therapy	26
Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners	26
Petite miracles: insight into the nano-management of scarless wound healing	26
Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics	26
Unveiling the potential of molecular imprinting polymer-based composites in the discovery of advanced drug delivery carriers	26
Which cryptic sites are feasible drug targets?	26
Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance	26
Sodium ion channels as potential therapeutic targets for cancer metastasis	26
Graph neural networks for automated de novo drug design	25
Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma	25
Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases	25
Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights	25
Recent development in the design of small ‘drug-like’ and nanoscale glycomimetics against Escherichia coli infections	25
Folate-mediated one-carbon metabolism: a targeting strategy in cancer therapy	25
Bio-inspired nanomaterials as novel options for the treatment of cardiovascular disease	25
Construction of cancer-on-a-chip for drug screening	25
Nanofibers as drug-delivery systems for antimicrobial peptides	25
Therapeutic potential of glutaminyl cyclases: Current status and emerging trends	24
Recent trends in targeted delivery of smart nanocarrier-based microbial enzymes for therapeutic applications	24
New views on endothelial dysfunction in gestational hypertension and potential therapy targets	24
Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities	24
Ferroptosis as a potential therapeutic target for age-related macular degeneration	24
Polycystic ovary syndrome: Current scenario and future insights	24
Causal inference in drug discovery and development	24
Best practices for managing and disseminating resources and outreach and evaluating the impact of the IDG Consortium	24
The hallmarks of tissue-agnostic therapies and strategies for early anticancer drug discovery	24
Advanced nanodelivery platforms for topical ophthalmic drug delivery	24
Overview of the Knowledge Management Center for Illuminating the Druggable Genome	24
Innovative strategies for measuring kinase activity to accelerate the next wave of novel kinase inhibitors	24
Transfer learning empowers accurate pharmacokinetics prediction of small samples	24
Optical tweezers for drug discovery	24
Drug repurposing: An effective strategy to accelerate contemporary drug discovery	23
Restoring the epigenome in Alzheimer's disease: advancing HDAC inhibitors as therapeutic agents	23
Molecular biomarkers of glial activation and injury in epilepsy	23
Towards holistic Compound Quality Scores: Extending ligand efficiency indices with compound pharmacokinetic characteristics	23
Active pharmaceutical ingredients (APIs) in ionic liquids: An effective approach for API physiochemical parameter optimization	23
The epigenetic impact of fatty acids as DNA methylation modulators	23
Polysaccharides as therapeutic vehicles in pancreatic cancer	23
Overcoming the protein corona in chitosan-based nanoparticles	23
Unlocking the potential of flavonoid-based co-crystal and co-amorphous systems	23
Formulation strategies for the development of high drug-loaded amorphous solid dispersions	23
Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors	23
Recent progress on rapid SARS-CoV-2/COVID-19 detection by CRISPR-Cas13-based platforms	23
Long noncoding RNAs (lncRNAs) in pancreatic cancer progression	22
Modelling the World – can deliberately infecting healthy volunteers really tell us much about what happens outside the clinic during an epidemic or pandemic?	22
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?	22
Contents page	22
AI for drug discovery is advancing rapidly: We need smart biology for it to fulfill its mission	22
Contents page 2	22
Applications of innovative technologies to the delivery of antipsychotics	22
ViralVacDB: A manually curated repository of viral vaccines	22
Cancer vaccines: An unkept promise?	22
Point-of-care diagnostics approaches for detection of lung cancer-associated circulating miRNAs	22
Driving success in personalized medicine through AI-enabled computational modeling	22
Exosome-cargoed microRNAs: Potential therapeutic molecules for diabetic wound healing	22
Small biotechs versus large pharma: Who drives first-in-class innovation in oncology?	22
Clinical research with targeted drugs in paediatric oncology	22
MicroRNAs and therapeutic potentials in acute and chronic cardiac disease	21
The emerging role of fatty acid binding protein 7 (FABP7) in cancers	21
Steps toward nebulization in-use studies to understand the stability of new biological entities	21
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	21
Spotlight on HIV-derived TAT peptide as a molecular shuttle in drug delivery	21
The dual role of photodynamic therapy to treat cancer and microbial infection	21
Contents page 2	21
Micro- and nanoformulations of paclitaxel based on micelles, liposomes, cubosomes, and lipid nanoparticles: Recent advances and challenges	21
Brain-derived neurotrophic factor (BDNF) in perinatal depression: Side show or pivotal factor?	21
On the pivotal role of drug discovery in sustainable EU pharma reform	21
Contents page	20
Microfluidics for personalized drug delivery	20
The role of venom proteomics and single-domain antibodies for antivenoms: Progress in snake envenoming treatment	20
VISTA: A Novel Checkpoint for Cancer Immunotherapy	20
An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads	20
Digital biomarkers for post-licensure safety monitoring	20
SETDB1, an H3K9-specific methyltransferase: An attractive epigenetic target to combat cancer	20
Contents page	20
Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity	20
Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids	20
Contents page	20
How missing value imputation is confounded with batch effects and what you can do about it	20
Electron diffraction: Accelerating drug development	20
Developing inhaled drugs for respiratory diseases: A medicinal chemistry perspective	19
Drug–drug co-amorphous systems: An emerging formulation strategy for poorly water-soluble drugs	19
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	19
Regulatory density as a means to refine current regulatory approaches for increasingly complex medicines	19
Leucine as an excipient in spray dried powder for inhalation	19
Towards Pharma 4.0 in clinical trials: A future-orientated perspective	19
Design, development, and technical considerations for dry powder inhaler devices	19
Illuminating the druggable genome: Pathways to progress	19
An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020	19
ET-traps: Potential therapeutics for preeclampsia	19
Statins and angiogenesis in non-cardiovascular diseases	19